Premaitha Share Discussion Threads

[ramas] 23/9/2018 10:44

But on the post results drop might be the smart play , I'll be monitoring closely

[goforgold1] 23/9/2018 08:41

https://m.spreadex.com/sports/why-spreadex/?gclid=EAIaIQobChMIi9DUks_Q3QIV7Z3tCh2WbAWSEAAYASACEgJMufD_BwESpreadex Has been shorting or been long Been trying make quick kill Just had a look at there web site. Which ever only got 1.6 % left Inwould day it was short. All good

[mhin2] 21/9/2018 22:08

not surprising twodegrees....

[twodegrees] 21/9/2018 16:16

Mr Myers is keen to keep adding

[ikeadave] 21/9/2018 09:03

The real bid is edging up, currently 13.711

Closing the week over 14p would be good!

[captain_kurt] 21/9/2018 08:17

Large buy reported.

Results next week

[small crow] 21/9/2018 08:14

Some confidence this am.

[ramas] 21/9/2018 08:13

Scary graph to buy on , I'll be pound cost averaging over the next few months as it's likely there will dips on the way up

[timojelly] 20/9/2018 18:59

Well, I think we'll be making all time highs by Christmas... mid 30s.

[ikeadave] 20/9/2018 18:51

Thanks Twix ... 25p doesn’t seem a particularly strenuous target!

[twix386] 20/9/2018 18:38

Tw's latest.....We have only been waiting three years for this and in the end it came as a complete surprise but a very pleasant one at that. At last Premaitha (NIPT) has settled its patent dispute with American bully boy giants Illumina. This bolt from the blue is great news and now means that a rapidly growing and profitable business will be, at last, valued on fundamentals and that will drive a re-rate which appears to be underway already.The shares are now 13.75p-14.25p and are a buy at up to 15p with a target to sell of 25p+ by Christmas. The deal, covering Premaitha's IONA non invasive pregnancy tests for Down's syndrome sees Premaitha free to sell its test in the EU and UK – where there were patent issues but will pay Illumina a royalty under a license agreement. Premaitha has also agreed to develop an IONA test that runs on Illumina sequencing technology, to be launched in early 2020; and within nine months of signing the agreements has committed to submitting documentation to a notified body for obtaining CE-IVD certification in Europe for the Illumina-compatible IONA test.Thereafter in the UK and in the Evil Empire Premaitha will work with its customers in the licensed territories to migrate to the IONA test based on Illumina sequencing technology. Premaitha will pay legal costs to settle all litigation to date. These have already been provided for are no more than £1 million.In the Rest of the World where Premaitha is seeing the most exciting growth it is business as normal and that means that for the rest of the year we can expect to see many more contracts signed and with the company already at a break even run rate as at March of this year, huge operational gearing will see it move into profit in the year to March 31 2019 with a massive ramp up thereafter.This stock will, given its sector and its growth potential (which is perhaps not potential but reality), be highly rated – easily mid to late teens – and as such the £54 million market cap today does not reflect the sort of profitability that will be achieved in a year beginning in less than six months time. BUY at sub 15p while you can.

[ramas] 20/9/2018 12:39

Not surprising to se the 3 baggers at least top slicing , over time I would expect the less risk averse to be joining the good ship NIPT

[frenchfry] 20/9/2018 10:46

Let the negativity with the share price continue short-term. What the latest announcement shows is that the Co.clearly has an expansionary vision which has already been worked on and developed behind the scenes as part of the settlement strategy.
Personally, I see this as an ideal point to top up prior to the next leg up in the share price The possibility of this being snapped up by a larger player must surely also have risen significantly.

[captain_kurt] 20/9/2018 09:55

Good appointment. Lots more near term newsflow to come imo

[scotty1] 20/9/2018 09:45

Premaitha" or the "Group")



Senior Commercial Appointment and Anticipated Directorate Change



Manchester, UK - 20 September 2018: Premaitha Health plc (AIM: NIPT), a leading international molecular diagnostics group, is pleased to announce the appointment of Mr Hayden Jeffreys to a senior commercial role within the Group and that he will be appointed to the Board as Group Commercial Director upon completion of the customary directorate appointment due diligence.



Hayden has over 20 years' experience in the clinical diagnostics industry, much of which has been spent within molecular diagnostics. He has held a number of senior international commercial and operational roles and has a proven track record of formulating and implementing commercial strategy, driving the next stage of global growth for businesses.



Most recently, Hayden was Chief Operating Officer of Cambridge Epigenetix, a privately held, early-stage diagnostic company. Prior to Cambridge Epigenetix, Hayden was Interim Chief Executive Officer for ERBA Diagnostics, a US-based publicly listed company. During his tenure at ERBA Diagnostics, he made a significant impact on business performance and on the organisation.



In addition, Hayden previously held senior positions within the ERBA group, including Head of Corporate Business Development and Strategy for ERBA Mannheim and Lumora, where he led its acquisition strategy and was responsible for licensing and partnership opportunities. He has also held senior positions at Lab21 and Gen-Probe. Hayden has expertise in leading and implementing business transformation including developing effective structures within organisations.



Hayden will be appointed to the board of directors of Premaitha in due course, subject to customary directorate appointment due diligence. A further announcement containing the disclosures required under the AIM Rules for Companies will be issued when this process has been completed.



Lyn Rees, Chief Executive Officer of Premaitha, commented: "Having worked in diagnostics businesses that provide both products and services, Hayden has an excellent understanding of the commercial dynamics of our business. He has a proven track-record of driving traction in new technologies within molecular diagnostics and a keen understanding of regulatory environments, which we will leverage as we seek to develop new partnerships and grow our footprint across new territories.



"I believe Hayden will be a valuable addition to the management team as we look to accelerate revenue growth and take advantage of a truly global opportunity."

[scotty1] 20/9/2018 09:34

Need subscription to read it

Premaitha settles Illumina dispute – this is great news: Buy at up to 15p – target 25p
By HotStockRockets | Thursday 20 September 2018

[frenchfry] 20/9/2018 08:08

The relative subdued reaction in the market to the settlement with Illumina can only be due to the absence of the finer detail of the actual terms. Despite this, it cannot be denied that the shackles restraining NIPT's trading over the last 3+ years have been removed, something which I do not believe the market has yet remotely appreciated.
That aside, I am wondering how long the PLC will remain headquartered in its present premises in Manchester. I visited the production facility soon after the Company's float. It would be fair to say that the building is not purpose-built and is a little tired, and may not be ideally suited to a company which is clearly now in expansion mode. I would not be surprised if the Company is not already considering its future location in terms of maximising efficiency as its turnover rapidly expands, either in newer,purpose-built premises nearby or even further afield.
Or perhaps be purchased with small change by one of the bigger players...

[5chipper] 20/9/2018 08:08

Nice mention in the Times today mentioning tie up with Immumina

[captain_kurt] 19/9/2018 23:02

Good post Ngen Yap.

Let's not forget Illumina next generation NGS will have Thermo Fisher tech!!

hxxps://www.eacr.org/news/thermo-fisher-scientific-and-illumina-sign-agreement-to-provide-research-market-broader-access-to-ion-ampliseq-technology

[ngen yap] 19/9/2018 22:56

Reflecting on the RNS today, don't think I could have expected a better settlement approach. We have drawn a line on the litigation. We have agreed a licensing deal which I expect royalty to be up to 10% only. We have committed to getting IONA test to be CE approved on Illumina machines by 2020. The latter may be viewed as a cost but one should view this as a significant new market opportunity IE we are now in bed with both the top two NGS providers and given IONA test is superior to all that is in the market today, our addressable market just doubled. The deal is global ie licensing of the patent across all relevant markets, so we are now truly a global provider!With the recent partnership with Coastal Genomics to bring more efficiencies in process, margin should remain healthy, and with Abnova, new product in cancer market, which I imagine will be on BOTH illumina and thermo machines.The cost of circa £1m to settle will cover both legal costs and I imagine royalties for UK and all other relevant territories until launch of tests on Illumina machines in 2020. Not bad.We are now truly global, with no more litigation threat anywhere, partnering with two of the largest players in the world. Some questioned what Thermo view is of this. Well, whatever the patent situation legally, they now have a company (remember they can own quite a chunk of Premaitha by conversion of loan) that is free the operate everywhere selling NIPT and other products. Yes, some machine sales loss but gain via sales of IONA tests.I expect strong trading update by end of month, and flurry of deals to come. Finally, we are unleashed.....perhaps those 50p options may just be achievable! Good luck all.

[captain_kurt] 19/9/2018 15:19

It's more balanced than that catch. Premaitha will now be able to sell into more countries than before using the illumina platfrom

[catch007] 19/9/2018 15:01

Whilst its good to see a form of resolution on the legal front it is very obvious the settlement deal is heavily skewed to benefit Illumina. NIPT do all the work and pay Illumina now for the privilege. That said the share price has been suppressed for a long time with the overhang of legal positions over the patents and a recovery uptick would be welcome. GLA

[timojelly] 19/9/2018 14:45

Looking like we are going to consoladate sideways today.

[dibs61] 19/9/2018 14:26

timojelly - that is exactly my take on it also.

Major Courtenay - explain what statement(s) in the RNS tell you that Illumina have 'complete ownership'?

[timojelly] 19/9/2018 14:05

Illumina do not hold any premaitha stock as far as I know. We will now distribute IONA using their platform and patents in UK, Japan, USA, and ( Europe when we get their patent CE approved) . We will continue to work with Thermo under OUR patent throughout rest of world.That's my take on it. Also we settle court costs of £1 million.We have now opened up a vastly increased market. No country off limits.